pre-IPO PHARMA

COMPANY OVERVIEW

HUYA Bioscience International sources pharmaceutical innovation originating in China for global development in international markets. With eight offices staffed with dedicated scientists throughout China, the Company has amassed the largest compound portfolio covering all major therapeutic areas. HUYA has emerged as the partner-of-choice for maximizing the value of biopharmaceutical innovation from China by developing both early and late stage drug candidates in concert with our partners primarily in oncology and cardiovascular disease


LOCATION

  • San Diego, CA, USA

  • THERAPEUTIC AREAS

  • Cardiovascular Disease
  • Oncology

  • WEBSITE

    https://www.huyabio.com/


    CAREER WEBSITE

    https://www.huyabio.com/careers/


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Jun 14, 2022

    HUYABIO INTERNATIONAL ANNOUNCES INITIATION OF HBI-3000 PHASE 2 TRIAL


    May 17, 2022

    HUYABIO INTERNATIONAL ANNOUNCES COMPLETION OF HBI-3000 PHASE 1 TRIAL AND FDA APPROVAL TO PROCEED WITH DOSE ESCALATION IN PHASE 2


    Dec 2, 2021

    HUYABIO Announces the Exclusive License of the KRAS Inhibitor from Shanghai Jemincare Pharmaceutical


    Dec 1, 2021

    Licensing Partner of Shenzhen Chipscreen Biosciences - HUYABIO International, Receives Regulatory Approval for Chidamide Monotherapy of Peripheral T-Cell Lymphoma(PTCL) in Japan


    Dec 1, 2021

    Jemincare gibt die exklusive Lizenz für den Kras-Inhibitor an HUYABIO bekannt USA - Deutsch India - English USA - English Latin America - español USA - español


    For More Press Releases


    Google Analytics Alternative